British Biotech Develops Vaccines that Ignite our Entire Immune System Against Disease

It may be cold, but we’re in one of the hottest spots for biotech – Oxford. We’re paying Vaccitech a visit to find out how its vaccines could help to beat cancer and infectious diseases.

Mission: Vaccitech’s aim is to develop vaccines that stimulate a strong T cell response, as well as the antibody response we tend to see. This is based on findings that some diseases are unsusceptible to antibody-based approaches. The company’s platform delivers two viral vector vaccines to provide a ‘primer’ and a ‘booster’ that give rise to a strong immune response by both CD4+ and CD8+ T cells. Its lead candidates target flu and prostate cancer, which are in Phase II and Phase I trials, respectively.

Comment: Vaccitech is taking current shortcomings to make a better vaccine. So far, Vaccitech looks to be succeeding. Its universal flu vaccine generates a strong T-cell response and a better antibody response than the standard flu virus alone. A Phase I trial tested the company’s prostate cancer vaccine in almost 50 patients, and a Phase II trial is planned to test it in combination with the checkpoint inhibitor, Opdivo.

In the flu vaccine field, Vaccitech will come up against fellow British, VirionHealth, which achieved£13M IPO to support the development of its universal vaccine. For cancer vaccines, Vaccitech will have to squeeze into a field jam-packed with interesting approaches, including BioNTech’s mRNA technology and Targovax’s peptides.


Image – e X p o s e / Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.